With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Nanoscope Therapeutics has said it plans to seek regulatory approval for its advanced retinitis pigmentosa gene therapy MCO-010 early this year.

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

The firm says it has a path forward for a Phase II/III registration-enabling study of NOUS-209 after positive meetings with the FDA.

The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.